Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma

SQ Wong; JM Raleigh; J Callahan; IA Vergara; S Ftouni; A Hatzimihalis; AJ Colebatch; J Li; T Semple; K Doig; C Mintoff; D Sinha; P Yeh; MJ Silva; K Alsop; H Thorne; DD Bowtell; DE Gyorki; GM Arnau; C Cullinane; D Kee; B Brady; F Kelleher; MA Dawson; AT Papenfuss; M Shackleton; RJ Hicks; GA McArthur; S Sandhu; SJ Dawson

Journal article

Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma

SQ Wong, JM Raleigh, J Callahan, IA Vergara, S Ftouni, A Hatzimihalis, AJ Colebatch, J Li, T Semple, K Doig, C Mintoff, D Sinha, P Yeh, MJ Silva, K Alsop, H Thorne, DD Bowtell, DE Gyorki, GM Arnau, C Cullinane Show all

JCO Precision Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2017

DOI: 10.1200/PO.16.00009

Abstract

Purpose Circulating tumorDNA(ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by 18F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) is unknown.Weassessed the role ofctDNAanalysis in combination with FDG-PET to monitor tumor burden and genomic heterogeneity throughout treatment. PatientsandMethodsWeperformed a comprehensiveanalysis of serialctDNAandFDG-PETin 52 patients who received systemic therapy for metastatic melanoma. Next-generation sequencing and digital polymerase chain reaction were used to analyze plasma samples from the cohort. Resu..

View full abstract

University of Melbourne Researchers

Related Projects (2)

ONCOGENIC SIGNALING AND CANCER THERAPY

Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental..

CIRCULATING TUMOUR DNA AS A NONINVASIVE BIOMARKER IN MELANOMA

The expanding repertoire of treatment options in melanoma is bringing into focus the need for improved ways to accurately monitor treatment ..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

Supported by a Peter MacCallum Cancer Foundation grant, the National Health and Medical Research Council (program grant APP1053792, project grant APP1107126), a Pfizer study grant, a Gundry Perpetual Endowment for melanoma research, and a Viertel Charitable Foundation Clinical Investigator Award. S.-J.D. was supported by a National Breast Cancer Foundation and Victorian Cancer Agency Fellowship. The Cancer Tissue Collection After Death (CASCADE) program was supported by the Peter MacCallum Cancer Foundation